Bone cancer therapy unexpectedly makes tumours less painful

A recent study has shown promising results in treating bone cancer that has spread to distant sites in the body, offering hope for both combating the disease and alleviating associated pain. This innovative approach involves disrupting the interaction between nerves and tumours, potentially revolutionizing cancer therapy by improving both survival rates and quality of life simultaneously.

According to experts like William Hwang from Harvard University, this new development represents a significant shift in cancer treatment paradigms, highlighting the potential for a more holistic approach to managing the disease.

Individuals with breast or prostate cancer that has metastasized to the bones often experience excruciating pain due to the growth of tumours that stimulate nearby nerves. While traditional treatments like radiotherapy and chemotherapy target these tumours, residual cancer cells can continue to interact with nerves, leading to persistent pain. Moreover, these conventional therapies can cause collateral damage to healthy tissues, necessitating long-term use of pain-relieving medications like opioids, which pose risks of addiction.

To address these challenges, a team of researchers led by Jiajia Xiang from Zhejiang University in China developed a novel nanotherapy using tiny lipid capsules containing DNA encoding the protein gasdermin B. This protein selectively kills cancer cells by creating pores in their membranes, while a compound called OPSA enhances the body’s immune response against cancer cells. The unique design of the nanotherapy ensures that gasdermin B is only produced in tumour cells, sparing healthy tissues.

In animal studies involving mice with breast cancer-induced bone tumours, the complete nanotherapy significantly reduced tumour size and improved survival rates compared to control groups. Notably, mice treated with the nanotherapy showed increased mobility in their affected limbs, indicating potential pain relief. Further analysis revealed a decrease in nerve density within tumours, suggesting a mechanism by which the nanotherapy mitigates pain.

The researchers speculate that the nanotherapy’s ability to enhance calcium ion uptake in cancer cells may disrupt the transmission of pain signals by depleting local calcium levels required for nerve function. This novel approach not only alleviates pain but also inhibits tumour growth by targeting the interaction between nerves and cancer cells.

While the results are promising, further research is needed to elucidate the precise mechanisms underlying the nanotherapy’s effects and optimize its therapeutic potential. The findings underscore the emerging trend of targeting the nervous system in cancer treatment, offering a new avenue for improving patient outcomes.

Although translating these findings into clinical practice may pose challenges, the prospect of human trials in the near future holds promise for transforming cancer therapy and enhancing patient care.